- Ultra-thinly traded Pulse Biosciences (NASDAQ:PLSE +32.5%) jumps out of the blocks on increased volume, albeit on turnover of only 19K shares, in response to its announcement that the former CEO and COO of Pharmacyclics, Bob Duggan and Maky Zanganeh, have taken a 17.1% stake in the company. Mr. Duggan owns ~2.1M shares while new board member Zangeneh owns ~279K shares.
- Development-stage Pulse's technology platform is called Nano-Pulse Stimulation (NPS). The company says NPS has potential as a cancer treatment. When NPS is applied directly to tissue it creates a transient opening of small pores in cell and organelle membranes that triggers a signaling cascade within a tumor that leads to cell death.